Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol Academic Article Article uri icon


MeSH Major

  • Circumcision, Male
  • Patient Acceptance of Health Care
  • Surgical Procedures, Operative


  • Close monitoring of kinetics of cytoreduction can rapidly distinguish between similar therapies, and the surrogate end-point may reduce the need for the long follow-up periods that may still be required to demonstrate differences in EFS. Continuous infusion of daunorubicin had less cardiotoxicity with faster antileukemic activity than bolus infusion. The MSK-NY-II protocol with a 86% 4-year EFS rate and a 95% DFS rate was a promising new regimen for the treatment of average-risk and high-risk ALL.

publication date

  • January 1993



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q

PubMed ID

  • 8221579

Additional Document Info

start page

  • 3120

end page

  • 30


  • 72


  • 10